NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q4 2025 (December 31)3holders −1
0new positions
1sold out
$0.07avg. 13F price*
At the end of Q4 2025, 3 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 1 sold out. The largest holders were Wolverine Asset Management LLC ($2K), Susquehanna International Group, LLP ($669) and UBS Group AG ($131).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $4.5M |
All 13F filers, Q3 2025 → Q4 2025: 2,349 shares bought and 3,030,755 shares sold, net −3,028,406 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Wolverine Asset Management LLC | — | Add +2.4% | 22,293 | $2K |
| Susquehanna International Group, LLP | — | Reduce -72.9% | 11,412 | $669 |
| UBS Group AG | — | Add +10188.9% | 1,852 | $131 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.